Vera Therapeutics, Inc.
Clinical trials sponsored by Vera Therapeutics, Inc., explained in plain language.
A clinical-stage biotechnology company developing treatments for autoimmune diseases, notably a monoclonal antibody for IgA nephropathy.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New monthly shot could tame rare kidney disease Results expected Sep 2026 (estimated) May already have reported ↗
-
Atacicept's Long-Term promise for kidney disease
Disease control By invitation onlyThis study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug …
Phase 2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New monthly shot could tame rare kidney disease
Disease control OngoingThis study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 9…
Phase 2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy
Disease control OngoingThis phase 3 trial tests atacicept, a weekly injection, in 376 adults with IgA nephropathy (Berger's disease). The goal is to reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo for about a year. The study is active…
Phase 3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC